Relmada Therapeutics, Inc. (RLMD)
NASDAQ: RLMD · Real-Time Price · USD
6.21
-0.24 (-3.72%)
At close: Mar 18, 2026, 4:00 PM EDT
6.34
+0.13 (2.09%)
After-hours: Mar 18, 2026, 7:46 PM EDT

Relmada Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Mar '26 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
455163126125105
Market Cap Growth
5814.31%-49.39%18.05%-79.01%19.50%-7.16%
Enterprise Value
441.52-29.22-65.32-122.06-86.8-12.4
Last Close Price
6.210.521.030.874.516.41
PE Ratio
--0.20-0.31-0.16-0.63-1.68
PB Ratio
21.780.440.360.190.600.99
P/TBV Ratio
20.830.440.360.180.380.95
P/FCF Ratio
--0.30-0.60-0.25-1.36-3.76
P/OCF Ratio
--0.30-0.60-0.25-1.36-3.76
EV/EBITDA Ratio
-0.350.630.760.690.20
EV/EBIT Ratio
-0.350.630.760.690.20
EV/FCF Ratio
-0.561.261.180.940.45
Net Debt / Equity Ratio
-1.47-1.26-1.13-1.06-1.02-1.11
Net Debt / EBITDA Ratio
0.240.540.930.921.691.93
Net Debt / FCF Ratio
0.350.871.871.432.314.21
Quick Ratio
2.684.367.9011.9414.089.30
Current Ratio
2.864.458.0012.2614.839.37
Return on Equity (ROE)
-249.73%-132.33%-87.51%-90.07%-80.14%-53.74%
Return on Assets (ROA)
-190.60%-117.03%-82.81%-85.72%-73.62%-51.71%
Return on Invested Capital (ROIC)
851.70%824.50%1100.11%2796.77%1659.13%1000.39%
Return on Capital Employed (ROCE)
-255.87%-138.80%-91.86%-92.49%-80.10%-54.99%
Earnings Yield
-12.34%-509.62%-318.45%-607.45%-158.76%-59.44%
FCF Yield
-8.78%-329.85%-166.63%-395.26%-73.44%-26.56%
Buyback Yield / Dilution
--1.57%0.00%-171.62%-150.22%-27.30%
Updated Nov 13, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q